Insider buying last 90 days
No open-market insider purchases were filed for ILMN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ILMN insider filing, plotted on the chart in Gekko.Open ILMN in Gekko
NASDAQ: ILMN
Illumina (ILMN) Stock Analysis & Forecast
Nov 4 close
$226.54−11.67 (−4.9%)
Gekko Brief
Nov 4 closeIllumina closed at $226.54 on 4 November 2026, -4.9% on the day. The price sits between the 50-day ($249.77) and 200-day ($177.39) moving averages, inside a 52-week range of $112.65 to $309.35. The GekkoIndex reads 63.9, in the Accumulation zone, up 13.2 points over five sessions. Gekko Fair Value is $254.48, so the price is 11% below it.
The next earnings report is due on 4 February 2027, 91 days away (after close). Over the last 8 reports the company beat the earnings estimate 7 times, with an average move of 12.5% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged -4.7% over the last 5 years, rising in 1 of them.
17 firms rate the stock: 8 buy, 6 hold and 3 sell, with a consensus target of $261.60. A typical daily move is about 7.8%, and a typical 20-day move about 8.1%. On the swing-trade checklist, 3 items read supportive and 2 read as a headwind (smart money, seasonality).
A plain summary of the figures as of the Nov 4, 2026 close.
Illumina price vs fair value
Close $226.54200-day averageGekko Fair Value $254.48
Illumina quick facts
- Market cap
- $34.21B
- P/E ratio
- 39
- Forward P/E
- 38.5
- EPS, TTM
- $5.81
- Revenue, TTM
- $4.54B
- Profit margin
- 19.7%
- Dividend yield
- —
- Beta
- 1.45
- Volume
- 3.03M avg 2.31M
- 1-year return
- +88.8%
- Typical daily move
- ±7.8%
- Typical 20-day move
- ±8.1%
- 50-day average
- $249.77
- 200-day average
- $177.39
- Next earnings
- Feb 4 after close
- Shares outstanding
- 151.2M
Illumina swing-trade checklist
Illumina scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendmixed
Averages disagree
Close $226.54 sits between the 50-day ($249.77) and 200-day ($177.39) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
63.9, Accumulation
Reading 63.9 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
11.0% below
Price is 11% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 91 days
Next report Feb 4, 2027, 91 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−4.7% on average
From this point in the calendar, the next 20 trading days averaged −4.7% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Illumina stock chart and price history
Illumina closed at $226.54 on Nov 4, 2026, +88.8% over the past year, inside a 52-week range of $112.65 to $309.35.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −17.2%
- 3 months
- +16.9%
- 6 months
- +58.9%
- 1 year
- +88.8%
The full ILMN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ILMN in Gekko
Follow Illumina through every session
Put ILMN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ILMN in GekkoFree for 7 days. No credit card required.
About Illumina
Illumina builds tools that read and interpret DNA, centering on sequencing and array technology. Its systems help laboratories and clinics turn genetic material into usable insight, supporting work in areas such as life sciences research, cancer diagnostics, reproductive health, and agriculture, along with newer areas of genomic study. The company is particularly associated with the instruments and related supplies that make this kind of large-scale genetic analysis possible.
Revenue comes from selling sequencing and genotyping instruments alongside the consumables they require, plus related services such as equipment servicing, licensing and development partnerships, and cancer screening tests. Customers include research institutions, universities, government and hospital laboratories, drug and biotech developers, diagnostic companies, and firms in consumer genomics. Illumina reaches these customers both by selling to them directly, across North America, Europe, Latin America and the Asia-Pacific, and through distributor partners who cover additional regions including the Middle East and Africa.
The company was founded in 1998 and is headquartered in San Diego, California. Its shares are listed on the NASDAQ under the ticker ILMN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- illumina.com
Illumina GekkoIndex: the smart money zone
Illumina’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.9, in the Accumulation zone, up 13.2 points over five sessions.
63.9Accumulation
Up 13.2 points over five sessions, from the Neutral zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 52 | −1.4% | −4.0% | ||
| Accumulation (current zone) | 167 | +0.6% | −1.0% | ||
| Neutral | 419 | +1.1% | +5.1% | ||
| Distribution | 58 | −0.1% | +3.7% | ||
| Selling | 1 | Too few readings yet | |||
Average ILMN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ILMN price, zone by zone.Track ILMN in Gekko
Is Illumina stock overvalued? Gekko Fair Value
Illumina trades 11.0% below Gekko Fair Value of $254.48, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Illumina shares are worth, recalculated every trading day.
$254.48
Gekko Fair Value, Nov 4, 2026
11.0% Undervalued
At the end of Aug 2026 the price was 8.2% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ILMN in Gekko
Illumina insider and Congress trading
No open-market insider purchases were filed for Illumina, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ILMN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ILMN, plotted on the chart in Gekko.Open ILMN in Gekko
Buybacks
Illumina has been buying back its own shares.
- Latest authorization
- $1.50B, Apr 30, 2026
- Bought back, quarter ended Jun 28, 2026
- $242.0M
- As a share of market cap
- 0.71%
- Trailing four quarters
- $656.0M
From company filings.
Unusual options activity last 30 days
1signal, 39% of the flagged premium in calls.
Latest: Bearish flow on Nov 3, $1.24M in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ILMN.
0added1opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Illumina earnings: next date and track record
Illumina reports on Feb 4, 2027, after the close (91 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Feb 4, 2027
Expected after the close, 91 days away
- EPS estimate
- $1.51
- Revenue estimate
- $1.23B
7 of 8reports beat the EPS estimate
±12.5%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 29, 2026 AI summary
- What they said
- Illumina reported Q3 2026 results above guidance range, driven by strong clinical sequencing demand and elevated NovaSeq X placements, with revenue, margin, and EPS all exceeding targets. The company advanced its Billion Cell Atlas initiative, now over halfway complete, with GSK joining the consortium. Illumina launched the BioInsight platform integrating analysis applications, AI models, and curated biological data, including SpliceAI2 which identified 17% more disease-relevant splice variants than competing models.
- Guidance
- Management raised full fiscal year 2026 guidance following strong Q3 execution and business momentum. The company stated it remains on track to achieve long-range financial targets, citing continued disciplined execution.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $1.62 est $1.36 | $1.17B est $1.15B | −18.3% |
| Jul 30, 2026 | $1.31 est $1.23 | $1.16B est $1.13B | +5.3% |
| Apr 30, 2026 | $1.15 est $1.07 | $1.09B est $1.07B | +12.8% |
| Feb 5, 2026 | $1.35 est $1.22 | $1.16B est $1.12B | −10.8% |
| Oct 30, 2025 | $1.34 est $1.17 | $1.08B est $1.07B | +30.0% |
| Jul 31, 2025 | $1.19 est $1.02 | $1.06B est $1.06B | −11.3% |
| May 8, 2025 | $0.97 est $0.94 | $1.04B est $1.03B | −0.8% |
| Feb 6, 2025 | $0.86 est $0.92 | $1.10B est $1.07B | −10.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Illumina stock forecast and analyst price targets
Analysts’ average 12-month price target for Illumina is $261.60, +15.5% from the last close, from 17 firms rating the stock in the last 90 days.
$261.60consensus 12-month target, +15.5% from the last close
Now $226.54Avg $261.60
Low $200High $310
Each firm’s latest rating in the last 90 days: 17 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Citi | $210 | −7.3% |
| Nov 2 | Freedom Capital Markets | $200 | −11.7% |
| Oct 30 | Canaccord Genuity | $300 | +32.4% |
| Oct 30 | Piper Sandler | $305 | +34.6% |
| Oct 30 | Evercore ISI | $275 | +21.4% |
−1.0%average 20-day move after past Accumulation readings
−4.7%average move over the next 20 trading days in the last 5 years
±7.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Illumina seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Illumina averaged −4.7% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.5% | 2 of 5 |
| Next 10 trading days | −8.5% | 1 of 5 |
| Next 15 trading days | −6.0% | 1 of 5 |
| Next 20 trading days | −4.7% | 1 of 5 |
| Next 30 trading days | −1.8% | 2 of 5 |
For scale, ILMN’s typical 20-trading-day move in either direction is about 8.1%.
Illumina market cap and key statistics
Illumina’s market cap is $34.21B, with a P/E ratio of 39 and revenue of $4.54B over the last twelve months.
Valuation
- Market cap
- $34.21B
- P/E ratio
- 39
- Forward P/E
- 38.5
- EPS, TTM
- $5.81
- Gekko Fair Value
- $254.48
Trading
- Volume
- 3.03M
- Avg volume, 20 days
- 2.31M
- 52-week high
- $309.35
- 52-week low
- $112.65
- Shares outstanding
- 151.2M
Financials
- Revenue, TTM
- $4.54B
- Profit margin
- 19.7%
- Return on equity
- 32.4%
- Quarterly earnings growth, YoY
- +45.9%
Risk and income
- Beta
- 1.45
- Typical daily move
- ±7.8%
- Typical 20-day move
- ±8.1%
Illumina stock news this week
Coverage of Illumina this week reads negative: 4 positive, 1 neutral and 5 negative headlines.
- REGN vs. ILMN: Which Stock Is the Better Value Option?Zacks Investment Research, Nov 4
- Illumina, Inc. (ILMN) Selected for Singapore Study of Around 450,000 PeopleTradingView, Nov 3
- Illumina selected to help bring precision medicine into everyday healthcare in SingaporeIllumina, Nov 3
- Illumina Inc. stock underperforms Monday when compared to competitorsMarketWatch, Nov 2
- Why Illumina (ILMN) is a Top Growth Stock for the Long-TermZacks Investment Research, Nov 2
- Don't Overlook Illumina (ILMN) International Revenue Trends While Assessing the StockZacks Investment Research, Nov 2
Illumina peers
Illumina’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
A peer links to its own page where one exists.
Illumina stock FAQ
What is Illumina’s market cap?
Illumina’s market cap is $34.21B at the Nov 4, 2026 close of $226.54, with 151.2M shares outstanding. The shares trade on a P/E ratio of 39.
What is the Illumina stock forecast?
The consensus analyst 12-month price target for Illumina is $261.60, +15.5% from the last close. Of the 17 firms that rated the stock in the last 90 days, 8 rate it a buy, 6 a hold and 3 a sell. Gekko doesn’t publish price predictions of its own.
Is Illumina stock overvalued or undervalued?
On Gekko’s estimate Illumina is undervalued: the Nov 4, 2026 close of $226.54 is 11.0% below Gekko Fair Value of $254.48. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Illumina report earnings next?
Illumina is expected to report on Feb 4, 2027, after the market closes (91 days away). Analysts expect earnings of $1.51 per share on revenue of $1.23B. Illumina beat the earnings estimate in 7 of its last 8 reports, moving 12.5% on average across the report.
What is Illumina’s 52-week high and low?
Illumina’s 52-week high is $309.35 and its 52-week low is $112.65; it closed at $226.54 on Nov 4, 2026, +88.8% over the past year. Over the last five years the shares peaked at $415.94 on Jan 12, 2022.
Is Illumina stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 2 as headwinds (smart money and seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Illumina?
Gekko flagged 1 unusual options signal in Illumina over the last 30 days, with $485K of flagged premium in calls and $751K in puts. The latest, bearish flow, was on Nov 3, 2026 with $1.24M in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Illumina the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.